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Statin use and the risk of colorectal 
cancer in a population-based 
electronic health records study
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Lorena Rodríguez-Alonso2,3, Alex Blasco10, Ana García-Rodríguez8, Rosa Morros5,9,11 & 
Victor Moreno  1,3,4,12
There is extensive debate regarding the protective effect of 3-hydroxy-3-methylglutaryl-coenzyme A 
reductase inhibitors (statins) on colorectal cancer (cRc). We aimed to assess the association between 
CRC risk and exposure to statins using a large cohort with prescription data. We carried out a case-
control study in Catalonia using the System for Development of Primary Care Research (SIDIAP) 
database that recorded patient diseases history and linked data on reimbursed medication. the study 
included 25 811 cases with an incident diagnosis of CRC between 2010 and 2015 and 129 117 frequency-
matched controls. Subjects were classified as exposed to statins if they had ever been dispensed statins. 
Analysis considering mean daily defined dose, cumulative duration and type of statin were performed. 
Overall, 66 372 subjects (43%) were exposed to statins. There was no significant decrease of CRC risk 
associated to any statin exposure (OR = 0.98; 95% CI: 0.95–1.01). Only in the stratified analysis by 
location a reduction of risk for rectal cancer was observed associated to statin exposure (OR = 0.87; 95% 
CI: 0.81–0.92). This study does not support an overall protective effect of statins in CRC, but a protective 
association with rectal cancer merits further research.
Colorectal cancer (CRC) is the third most common cancer worldwide1 and its incidence is still rising in many 
low and middle income countries2. Focus on primary prevention and screening is necessary in order to reduce 
the incidence and mortality of this cancer. Although lifestyle risk factors have been identified in CRC3, rand-
omized trials have failed to show a reduction of adenomas recurrence with diet4–6 or dietary supplements7,8. A 
large body of evidence has shown that nonsteroidal anti-inflammatory drugs (NSAID), particularly acetylsali-
cylic acid (ASA), reduce the risk of colorectal neoplasia9,10 but with possible adverse events11. Indeed, a safe and 
effective CRC chemoprevention agent in average-risk population would help reducing the incidence of colorectal 
neoplasia.
Statins, inhibitors of 3-hydroxy-3-methyl-glutaryl-coenzyme A reductase, are a widely used and well-tolerated 
class of drugs for the treatment of hypercholesterolemia. Previous studies indicate their possible role in cancer 
chemoprevention12,13, with controversial results14–16. In addition to their main effect on cholesterol synthesis, stat-
ins may cause a number of other pleiotropic effects that may influence tumorigenesis, such as antioxidant activity, 
effects on cell adhesion, or angiogenesis17. In vitro, statins have shown anti-proliferative and pro-apoptotic effects 
on human CRC cell lines, and also in tumour xenograft models18,19. Studies analysing the effects of exposure to 
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statins on the prevention or prognosis of colorectal neoplasia have shown controversial results, which have been 
proposed to be due to heterogeneity amongst drugs, or to effects restricted to some subgroup of patients14–16,20.
In this observational study we have analysed a population-based health records database aiming to examine 
the association between statins, their subtypes and pattern of use, and CRC risk.
Methods
Data source. Subjects were selected from the Information System for Development of Primary Care Research 
(SIDIAP) database (www.sidiap.org)21, which comprises clinical information routinely collected by primary care 
professionals of the Catalan Institute of Health. This database includes information from 5.8 million people in 
Catalonia (almost 80% of the population) that have ever contacted the public health system since 2005. The data 
retrieved included routine clinical data, such as diagnoses and health measurements, and was linked to infor-
mation on dispensed prescriptions generated by pharmacies’ claims for reimbursement by the Catalan Health 
System. Drugs were coded according to the Anatomical Therapeutic Chemical (ATC) classification system22, and 
the date and quantity of the drug withdrawn from the pharmacy were recorded. Irreversible encoding of patient 
identifiers ensured anonymization of the information in the SIDIAP study database. The quality of SIDIAP data 
has been previously documented, and it has been used to study the epidemiology of health outcomes23.
All procedures performed in the study involving data from human participants were in accordance with the 
ethical standards of the institutional research committee, and with the 1964 Helsinki Declaration and its later 
amendments or comparable ethical standards. No informed consent was requested to the participating individu-
als, since this study was based on anonymized data routinely collected. No variables with potential to identify spe-
cific individuals were retrieved. The study protocol was approved by the Ethics Committee for Clinical Research 
of IDIAP Jordi Gol and all applicable regulatory requirements were fulfilled. The study was registered in ENCePP 
database with code EUPAS12697.
Study design. A population-based case-control study nested within the cohort of subjects receiving primary 
care from the Institut Català de la Salut was conducted. The flow chart of the study is described in Fig. 1. The 
cohort of subjects registered in SIDIAP with at least one healthcare interaction in last 3 years (n = 5 830 562) was 
limited to adult population, aged 18 to 90 years (n = 4 664 450). Cases identified with a recorded incident diag-
nosis of colon or rectum (codes C18, C19, and C20 of the International Classification of Diseases 10th Revision 
[ICD-10]) within the period January 1, 2010 to December 31, 2015 were identified. Those cases with a diagnosis 
of appendix cancer (C18.1) were excluded to avoid the inclusion of carcinoid tumours which are more frequent 
in that location.
A random stratified selection of controls was obtained using the same SIDIAP database. For each case, five 
controls were randomly selected from the set of all subjects in the database without prior CRC and alive at the 
time of diagnosis of the case, with the same age (±5 years) and sex and living in the same region defined by the 
primary healthcare centre catchment area. For cases, the disease onset date, defined as the earliest CRC diag-
nosis date registered, was set as the index date. For controls, the index date of their matched case was applied. 
Information regarding comorbidities and drug use was truncated to that recorded prior to the index date for cases 
and controls.
Figure 1. Population flowchart and study design. SIDIAP includes subjects that have interacted with the 
Catalan public health system (~74% of the total Catalan population). The study selected all CRC patients in the 
period 2010–2015 aged 18 to 90 years. Cases were incident diagnosis of colon or rectum (ICD-10 codes C18, 
C19, and C20). For each case, 5 matched controls of the same sex, age ± 5 years and health area were selected 
and assigned the case diagnosis date as index date for exposure assessment. Appendix cancer (C18.1) cases were 
excluded.
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To assess if the codes used for case identification were reliable and exhaustive, and also to obtain an indirect 
measure of the external validity of our sample, we estimated the expected number of incident CRC cases in the 
population covered by the database according to cancer registries in Catalonia that contribute to the International 
Agency for Research on Cancer (IARC) publication Cancer Incidence in Five Continents (CI5) Volume XI24. 
The age-specific incidence rates of colon and rectum cancer estimated in the Tarragona and Girona cancer reg-
istries for 2012 were downloaded from https://ci5.iarc.fr. The age-specific rates were averaged over registries 
and summed for colon and rectum, then multiplied by the total Catalan population for the same age groups and 
period downloaded from https://www.idescat.cat. The population was corrected multiplying by 0.8 to account 
the average SIDIAP cumulative coverage on the studied period. Supplementary Fig. 1 shows that the number and 
age-sex distribution of the cases observed was similar to those expected.
Exposure variables. Patients were classified as exposed to statins if they had retrieved at least one dispensa-
tion with an Anatomical Therapeutic Chemical code beginning with “C10AA”; otherwise, they were classified as 
unexposed. We also obtained exposure data for nonsteroidal anti-inflammatory drugs (NSAIDs) including aspi-
rin (M01A, N02BA, N02BB, and B01AC06) as they potentially could confound the association between statin use 
and cancer risk, and other lipid lowering drugs (C10AB, C10AC, C10AD, C10AX). Daily defined doses (DDD) 
for each dispensed prescription were calculated by multiplying the container pills by dose (in mg) and dividing 
by the World Health Organization defined DDD (in mg) for each individual drug22. The average dose for each of 
these duration categories was established, dividing the sum of DDD by the interval length. Finally, to measure the 
effect of timing of exposure, we compared non-users to the subjects exposed exclusively 1 month to 5 years before 
the index date (short exposure) and the subjects exposed throughout the period of more than 5 years before the 
index date (long exposure). We chose ≥5 years as a cut-off point of long term, according to the mean of follow-up 
and statin use in randomized controlled trials.
In order to compare the results with previous studies, statins were classified as lipophilic (atorvastatin, fluvas-
tatin, lovastatin, simvastatin) or hydrophilic (pravastatin and rosuvastatin) and, by effectiveness in lowering LDL 
cholesterol levels, as low-potency (fluvastatin, lovastatin, pravastatin, simvastatin) and high-potency (atorvastatin 
and rosuvastatin)25.
confounders. The potential confounders identified a priori for this analysis were age, sex, socioeconomic 
status, region, year, body mass index (BMI), tobacco, alcohol, comorbidity conditions and NSAID use3,9,10. 
Socioeconomic status was evaluated using the MEDEA socioeconomic deprivation score26, which was divided 
into quintiles for the analysis. Chronic comorbidity conditions considered for multivariable adjustment included 
those associated with CRC in the data: hypertension, hyperuricemia, diabetes, osteoarthritis and spondyloar-
thropathy, chronic lower respiratory diseases, extrapyramidal and movement disorders, episodic and paroxysmal 
disorders, mental and behavioural disorders, chronic kidney disease, heart failure, cerebrovascular disease, liver 
disease, insomnia, osteoporosis, peptic ulcer, inflammatory bowel disease. Conditions clearly defined as indica-
tions of statins (dyslipidaemia and cardiovascular disease) were not considered for adjustment, since they are in 
the explored causal path.
Statistical analysis. Odds ratios (OR) and 95% confidence intervals (95% CI) were calculated from uncon-
ditional logistic regression models. We compared the effect of no use to any use of drug and assessed effects 
of dose (DDD) and duration of statin use. We also explored the effect of the type of the statin (potency and 
lipophilicity). Subgroup analyses were performed according to sex, age groups, NSAID use and cancer location 
(colon or rectum). Missing data for body mass index (BMI) was imputed using the prediction of a linear model 
according to age, sex and, outcome status (63% had complete data). To avoid models with many parameters, an 
adjustment score was built from the predictions of a logistic regression model for CRC that included all potential 
confounding covariates, without selection strategies. This adjustment score was efficient to render all potential 
confounders non-significantly associated to CRC. All logistic regression models included the adjustment score. 
P-values were derived from likelihood ratio tests. Statistical analysis was carried out using R statistical software (R 
Foundation for Statistical Computing, Vienna, Austria).
Results
Baseline characteristics and statin exposure. Characteristics of the study population according to sta-
tin use are presented in Table 1. During the study period there were 25 811 CRC cases which were matched by 
sex, age at time of index date (±5 years), and healthcare region to 129 117 controls. A total of 66 372 (42.8%) sub-
jects were ever users of 3-Hydroxy-3-methylglutaryl-coenzyme A reductase inhibitors at the index date, 55 008 
(42.6%) were controls and 11 364 (44.0%) CRC cases. Statin users were older with only 3.2% being less than age 
55 years at entry (median age 74 years for users and 67 years for non-users). Statin consumption was associated 
with age, male sex, data of entry in the cohort, higher BMI, former smoking, severe alcohol consumption and, 
higher NSAID prescription (Table 1). Statin users were more likely to have comorbidities (see Supplementary 
Table 1).
The most frequent statin used was simvastatin (n = 48 907, 31.6% of all subjects) followed by atorvastatin 
(n = 25 198, 16.3% of all subjects) (Table 2). Of the 66 372 subjects ever exposed to any statin, 32 559 (49.1.5%) 
were long term users of statins (≥5 years). There were 22 995 (34.7%) individuals that were ever exposed to more 
than one different statin. The most common multiple exposure was simvastatin and atorvastatin, followed by 
simvastatin and pravastatin (Table 2).
A detailed table with the characteristics of the study population for cases of CRC and controls is presented in 
Supplementary Table 2. The environmental variables associated with CRC were lower BMI, former smoking and 
alcohol consumption. The median number of months on statin use was 58 months for both cases and controls.
4Scientific RepoRtS |         (2019) 9:13560  | https://doi.org/10.1038/s41598-019-49877-5
www.nature.com/scientificreportswww.nature.com/scientificreports/
Statin use and colorectal cancer. There was no overall association of statin use with CRC risk (OR = 0.98; 
95% CI: 0.95–1.01, P = 0.11) (Table 2). The analysis of duration of exposure showed a significant 11% increase of 
risk for exposures to statins shorter than 5 years, while the analysis of cumulated exposure as derived from sum 
of DDDs per subject was not significant. Moreover, the risk of CRC was similar in patients with current or former 
exposure, and also among those who stopped taking statins 6 months, 12 months and 36 months before the index 
date.
No differences were observed when statins were classified by their potency or lipophilicity. The analysis of 
specific statins did not show differential effects regarding CRC risk. Finally, as Supplementary Table 3 shows, 
there was no interaction according to age groups (P-value for interaction = 0.06) nor gender (P-value for inter-
action = 0.09). There was a significant interaction for NSAIDs exposure, so that exposure to was protective in 
NSAIDs users but increased risk in non-users (P-value for interaction <0.01).
Statin use and rectal cancer. We performed a stratified analysis to determine whether CRC location 
influenced the effect of statins (Table 3). A statistically significant interaction of tumour location was observed 
(P < 0.001), with a significant reduction of 13% in the risk of rectal cancer (adjusted OR = 0.87; 95% CI: 0.81–
0.92, P < 0.001), but not of colon cancer (adjusted OR 1.00; 95% CI: 0.97–1.03, P = 0.91). However, no consistent 
dose-effect was seen when analysing duration and dose. All types of statins showed similar significant associa-
tions for rectal cancer.
Analysis of other lipid lowering drugs. A significantly increased risk of CRC was observed for subjects 
exposed to bile acid sequestrants (OR 1.33; 95% CI: 1.12–1.57, p = 0.001), but no significant association with CRC 
was seen for exposures to neither fibrates nor nicotinic acid, independently on location, statin potency or dose 
(Supplementary Table 4).
Characteristic
Statin non-users Statin users
ORa 95% CI P-value (trend)n % n %
Age
18–55 years 13076 17.6 1778 3.2 1
55–65 years 17948 24.2 8793 16.0 3.59 3.40–3.80
65–75 years 17945 24.2 17560 31.9 7.17 6.79–7.56
75–85 years 18065 24.4 20912 38.0 8.50 8.06–8.97
85–95 years 7075 9.5 5965 10.8 6.23 5.86–6.62 <0.0001
Sex
Male 43557 58.8 33112 60.2 1
Female 30552 41.2 21896 39.8 0.93 0.91–0.96 <0.0001
Year of entry (years)
2010 12871 17.4 7743 14.1 1
2011 12913 17.4 8426 15.3 1.11 1.07–1.16
2012 12884 17.4 9582 17.4 1.24 1.19–1.29
2013 12754 17.2 10297 18.7 1.33 1.28–1.38
2014 12858 17.4 10500 19.1 1.38 1.33–1.44
2015 9829 13.3 8460 15.4 1.43 1.37–1.49 <0.0001
Body Mass Index
≤25 kg/m2 12217 16.5 8769 15.9 1
25.1–30.0 kg/m2 47902 64.6 29691 54.0 0.91 0.88–0.94
>30 kg/m2 13990 18.9 16548 30.1 1.67 1.61–1.73 <0.0001
Tobaccob
Non-smoker 35247 61.3 31761 61.0 1
Current smoker 10875 18.9 6608 12.7 0.94 0.91–0.98
Former smoker 11392 19.8 13701 26.3 1.42 1.38–1.47
Alcoholb
None/mild 30591 63.1 30927 64.5 1
Moderate 16524 34.1 16010 33.4 1.02 0.99–1.05
Severe 1387 2.9 1045 2.2 0.89 0.81–0.96 0.004
NSAIDs
Non-users 31529 42.5 8525 15.5 1
Users 42580 57.5 46483 84.5 3.61 3.51–3.71 <0.0001
Table 1. Characteristics of the study according to statin use (controls only, N = 129117). aAdjusted for age and 
sex. bVariables with missing data. NSAID: Nonsteroidal anti-inflammatory drugs
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Discussion
In this study, based on the SIDIAP database, which is representative of the Catalan population, we found a high 
prevalence of exposure to statins, above 40% both in cases and controls. We observed that exposure to statins was 
not significantly associated with the overall risk of CRC, but might be associated to a modestly reduced rectal 
cancer risk. For colon cancer or the combination of colon and rectal cancer (colorectal), there was no decrease in 
risk associated with statin use. There were no consistent associations observed for duration and cumulated dose 
of statin exposure and rectal cancer, while the protective association was similar for diverse statin types. Besides, 
exposure to acid bile sequestrants showed an increase of risk of 33%.
Previous case-control and cohort studies have suggested that statins could play a role in cancer chemopre-
vention12,13. However, data from clinical trials have not confirmed the protective effect seen in observational 
studies14. Recently, two meta-analyses and one systematic review including 40, 42, and 59 individual studies, 
respectively14,15,20, reported a modest reduction in risk of CRC among statin users. In contrast, previous studies 
that linked pharmacy and cancer registry databases found no associations between statin use and CRC risk27–34. 
Our study adds further evidence to the lack of a relevant effect of statins on the risk of incident CRC, supporting 
that any effect, if present, is of marginal magnitude. Our observation of a significant 11% increase of risk related 
to statin exposures shorter than 5 years is isolated, not found in other analysis such as the one exploring tumour 
location, and thus is of uncertain value.
Liu et al.15 showed in a stratified analyses a significant decreased association of risk in rectal cancer and for 
lipophilic statins, but this was limited to observational studies, and not when data was obtained from clinical 
trials. Our study has also observed that statin use may be selectively associated with reduced risk of rectal cancer. 
The reasons for this disparity in site association are unclear. Though colon and rectum are very similar at the 
molecular level35, environmental factors36,37 such as tobacco and physical activity38 differ in their role in their car-
cinogenesis. Moreover, there are clear differences among these two cancer locations regarding anatomic, embry-
ologic, and physiologic differences39,40.
The analysis of the other lipid-lowering agents was to rule out confusion by indication, and it detected that 
bile acid sequestrants increased the risk of CRC, but all other lipid-lowering agents were not associated with CRC, 
similarly to statins. This finding was unexpected; while bile acid sequestrants are mainly used for the treatment 
of dyslipidaemia as they reduce low-density lipoprotein cholesterol41, they are less used than statins due to their 
poor tolerability (only 0.7% of our population was exposed), so that generally they are only prescribed to patients 
intolerant to statins or with severe dyslipidaemia. The role of bile acids on colorectal carcinogenesis has been 
Controls CRC cases
ORa 95% CI P-valuen % n %
Overall effect
Non-user 74109 57.4 14447 56.0 1 0.11
Statin user 55008 42.6 11364 44.0 0.98 0.95–1.01
Durationb
Non-user 74109 57.4 14447 56.0 1 0.0002
<5 years 22515 17.4 4568 17.7 1.11 1.04–1.18
≥5 years 27002 20.9 5557 21.5 0.96 0.93–1.00
Cumulative dose
Non-user 74109 57.4 14447 56.0 1 0.06
<709 DDD 18344 14.2 3784 14.7 1.00 0.96–1.04
709–2370 DDD 18307 14.2 3817 14.8 0.98 0.94–1.02
>2370 DDD 18357 14.2 3763 14.6 0.95 0.91–0.99
Lipophilicity
Non-user 74109 57.4 14447 56.0 1 0.38
Lipophilic 45456 35.2 9418 36.5 0.98 0.95–1.01
Hydrophilic 2844 2.2 567 2.2 0.96 0.87–1.05
Both 6708 5.2 1379 5.3 0.96 0.91–1.03
Statin potency
Non-user 74109 57.4 14447 56.0 1 0.13
Low potency 33139 25.7 6821 26.4 0.98 0.94–1.01
High potency 7900 6.1 1678 6.5 1.01 0.96–1.07
Both 13969 10.8 2865 11.1 0.96 0.91–1.00
Type of statin
Simvastatin 40584 31.4 8323 32.2 0.97 0.94–0.99 0.02
Atorvastatin 20839 16.1 4359 16.9 0.99 0.96–1.03 0.75
Pravastatin 7964 6.2 1635 6.3 0.98 0.93–1.04 0.48
Fluvastatin 3447 2.7 698 2.7 0.98 0.90–1.06 0.59
Lovastatin 3132 2.4 677 2.6 1.04 0.96–1.13 0.35
Rosuvastatin 1915 1.5 372 1.4 0.92 0.82–1.03 0.16
Pitavastatin 325 0.3 69 0.3 1.03 0.79–1.34 0.83
Simvastatin + atorvastatinc 11353 8.8 2355 9.1 0.97 0.93–1.02 0.29
Simvastatin + pravastatinc 3973 3.1 832 3.2 1.00 0.92–1.08 0.95
Table 2. Statin use and CRC risk. aAdjusted for age, sex, socioeconomic status, region, year, body mass index, 
smoking, alcohol, comorbidities and nonsteroidal anti-inflammatory drugs use. bVariables with missing data. 
cNon-users or users of only one of the two drugs as reference category.
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widely studied42, and one trial had already reported a potential increase of CRC for long term use of cholesty-
ramine back in 199243, but we have found no other references analysing the effect of these drugs on CRC, which 
may merit further research.
Potential limitations of this study, common to others using routinely collected data, include the lack of indi-
vidual validation of exposure or cancer status. Nevertheless, SIDIAP has been widely used for other epidemi-
ologic studies, and previous validation studies have shown that the collected information is reliable regarding 
disease coding21,23,44. Regarding cancer location, we found a high proportion (72%) of cases classified as “colon 
not specified” (C18.9), and a lower number of rectal cancers than expected (18% observed vs 48% expected45). 
However, the total number of cases combining colon and rectum was consistent with those expected based on 
the incidence data published by the Catalan cancer registries (Supplementary Fig. 1)45. While it is plausible that 
some rectal cancers might be coded as “colon cancer not specified”, we can assume that the specificity of the rectal 
cancer location should be high. Misclassification was probably independent of statin use, and although might 
reduce statistical power for the analysis of rectal cancer, any bias, if existent, should be towards the null hypothe-
sis. Regarding exposure, we used actually dispensed prescriptions at pharmacies. Though there is no way to prove 
that dispensed prescriptions were actually consumed, data on dispensed drugs is more reliable than electronic 
prescriptions, which may overestimate exposure at the expense of prescriptions that are never dispensed at phar-
macies. Another limitation was that we could not adjust for some risk factors for CRC like physical activity, diet 
or family history of CRC, because these data were not available or did not reach usable quality. Finally, we have 
observed in our population that a lower BMI was associated with CRC. This is a typical finding in case-control 
studies, because the BMI data is registered close to the cancer diagnosis, in order to objectivize weight loss caused 
by the CRC as a part of the diagnostic procedures, while controls may have BMI recorded more often when obe-
sity is requiring a clinical intervention by primary care physician.
The strengths of this study include the large sample size, and the high representativeness of the population, 
since SIDIAP includes data on roughly 80%% of the Catalan population. Because SIDIAP contains data col-
lected in routine practice conditions, the likelihood of observer bias is minimized. The use of electronic medical 
records and invoicing databases allowed us to overcome memory bias. Despite the study period was limited to 
2010–2015, individual medication data was available from 2005 onwards, which allowed us to study a long period 
of exposure, ensuring a minimum of 5 years before the CRC diagnosis. This is of paramount importance when 
studying diseases with long latency such as cancer, and, in fact short exposure time is a major criticism to statin 
randomized trials.
In conclusion, this study adds further evidence about the lack of a relevant association between statin utili-
zation and risk of incident CRC. While we found no association between the use of statins and overall colorectal 
cancer risk, the suggestive evidence of a decrease in risk for rectal cancer requires further research.
Data Availability
The datasets generated and analysed during the current study are not publicly available due to restrictions im-
posed by the data provider (the Information System for Development of Primary Care Research, SIDIAP) but 




P-valueb P-interactioncn % n % ORa 95% CI n % ORa 95% CI
Overall effect
Non-user 74109 57.4 11754 55.3 1 0.91 2693 58.9 1 <0.001 <0.001
Statin user 55008 42.6 9488 44.7 1.00 0.97–1.03 1876 41.1 0.87 0.81–0.92
Durationd
Non-user 74109 57.4 11754 55.3 1 0.001 2693 58.9 1 <0.001
<5 years 22515 17.4 3813 18.0 0.99 0.95–1.03 755 16.5 0.96 0.82–1.11
≥5 years 27002 20.9 4636 21.8 0.98 0.95–1.02 921 20.2 0.85 0.79–0.93
Cumulative dose
Non-user 74109 57.4 11754 55.3 1 0.10 2693 58.9 1 <0.001
<709 DDD 18344 14.2 3167 14.9 1.03 0.98–1.07 617 13.5 0.87 0.80–0.96 <0.001
709–2370 
DDD 18307 14.2 3202 15.1 1.01 0.97–1.06 615 13.5 0.85 0.78–0.93
>2370 DDD 18357 14.2 3119 14.7 0.96 0.92–1.01 644 14.1 0.87 0.80–0.96
Lipophilicity
Non-user 74109 57.4 11754 55.3 1 0.94 2693 58.9 1 <0.001 <0.001
Lipophilic 45456 35.2 7851 37.0 1.00 0.97–1.04 1567 34.3 0.88 0.82–0.94
Hydrophilic 2844 2.2 490 2.3 1.01 0.92–1.12 77 1.7 0.70 0.55–0.88
Both 6708 5.2 1147 5.4 0.99 0.92–1.05 232 5.1 0.87 0.76–1.00
Statin potency
Non-user 74109 57.4 11754 55.3 1 0.28 2693 58.9 1 <0.001 <0.001
Low potency 33139 25.7 5690 26.8 1.00 0.97–1.04 1131 24.8 0.87 0.81–0.94
High potency 7900 6.1 1414 6.7 1.05 0.99–1.12 264 5.8 0.86 0.75–0.98
Both 13969 10.8 2384 11.2 0.98 0.93–1.03 481 10.5 0.86 0.78–0.96
Table 3. Analyses of statins effect according to CRC location. aAdjusted for age, sex, socioeconomic status, 
region, year, body mass index, smoking, alcohol, comorbidities and NSAID use. bP-value for trend. cP-value for 
the interaction between colon and rectum. dVariables with missing data.
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